Enhancing ADHD Driving Performance With Stimulant Medication
Recruitment status was: Recruiting
Among children, attention-deficit/hyperactivity disorder (ADHD) is associated with an increased risk for accidents, especially bicycle and pedestrian (Leibson 2001; Jensen 1988; DiScala 1998). Anywhere from 40% to 80% of children diagnosed with ADHD continue to display symptoms of the disorder into adolescence(Barkley 1990; Gittelman 1985). Adolescents with ADHD are also at an increased risk for driving-related accidents, being 2 to 4 times more likely to experience a motor vehicle accident (Barkley 1993; Barkley 1996; Cox 2000), 4 times as likely to be at fault in the accident (Barkley 1993), and over 3 times more likely to incur associated injuries as a result of the accident(Murphy 1996).
Stimulant treatment with immediate-release methylphenidate (IR MPH) has been demonstrated to improve driving performance in adolescents with ADHD.
Hypothesis to be Tested:
- Main study: Just as stimulant medication improves simulation and on-road driving performance of ADHD teenagers, it is hypothesized that stimulant medication will improve routine driving performance.
- Substudy - Extended wear (15 hours) of Daytrana will lead to safer driving late in the evening (22:00 and 01:00), when the most dangerous driving mishaps are most likely to occur, and the next morning at 09:00.
|Attention Deficit Hyperactivity Disorder||Drug: Methylphenidate Transdermal System|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
|Official Title:||Enhancing ADHD Driving Performance With Stimulant Medication|
- Video recording of driving mishaps [ Time Frame: 6 months ]
|Study Start Date:||July 2007|
|Estimated Study Completion Date:||July 2009|
|Estimated Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
Drug: Methylphenidate Transdermal System
Daytrana wear time up to 15 hours
Other Name: Brand name = Daytrana
No Intervention: 2
No treatment for ADHD
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00572026
|Contact: Daniel J Cox, PhDfirstname.lastname@example.org|
|Contact: Margaret Davisemail@example.com|
|United States, Virginia|
|University of Virginia||Recruiting|
|Charlottesville, Virginia, United States, 22908|
|Contact: Daneil J Cox, PhD 434-924-5314 firstname.lastname@example.org|
|Contact: Margaret Davis 434-924-0481 email@example.com|
|Principal Investigator: Daniel J Cox, PhD|
|Principal Investigator:||Daniel J Cox, PhD||University of Virginia|